Inflammatory Bowel Diseases
Conditions
Keywords
Infliximab, Proactive drug monitoring
Brief summary
The purpose of the study is to assess whether a proactive therapeutic drug monitoring strategy, introduced early during treatment, improves Infliximab (IFX) durability, efficacy and safety in children and young adults with inflammatory bowel disease. Patients with an indication to receive IFX, based on current clinical practice recommendations, will receive the drug either based on IFX concentrations determined before every IFX infusion, starting from the third infusion, or at standard dosing. Approximately 90 patients will be included in this research study. Patients enrolled will be in the study for approximately 12 months.
Detailed description
Inflammatory Bowel Disease (IBD) are relapsing disorders with progressive bowel damage leading to long-term disability. Infliximab (IFX), is a highly effective and commonly used biologic in IBD. However, up to 40% of patients do not respond to treatment or lose response over time. Low-serum IFX concentrations and the development of antibodies to IFX (ATI) are two major factors affecting IFX efficacy, durability and safety. Standard IFX dose is administered as an IV (in the vein) infusion at 5 mg/kg in a 0, 2, and 6 weeks induction regimen followed by a maintenance regimen with infusions every 8 weeks. This standard dosing is extrapolated from adult studies. IFX has a highly variable pharmacokinetic and pharmacodynamics that is dependent on body weight, disease extent, levels of inflammation and the presence of ATI. In children and young adults with IBD all these factors often result in low-serum IFX concentrations. Proactive therapeutic drug monitoring, consists in the measurement of drug concentrations on patient's blood, in order to adjust the following administrations (dosing or interval) and maintain a desired concentration of the medication in the body. This study seeks to determine whether a proactive therapeutic drug monitoring strategy can improve IFX durability, efficacy and safety in children and young adults with IBD. The study will involve approximately 90 patients, aged 6 to 17 years, with IBD. All the patients enrolled in the study will receive IFX at 5mg/kg at week 0, 2 and 6. At week 6 patients will be randomly assigned to receive IFX treatment either based on IFX concentrations determined before every IFX infusion (intervention group) or at standard dosing (control group). Patients will participate in the study for 54 weeks (approximately 12 months) or until IFX discontinuation. During the study, patients will visit the study center at the time of every IFX infusion or in case of disease flares.
Interventions
DRUGInfliximab
Infliximab
Sponsors
IRCCS Burlo Garofolo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Anti-TNF naïve children and adolescents, 6-17 years, with a diagnosis of IBD confirmed by a prior endoscopic biopsy that is consistent with the diagnosis 2. Indication to start anti-TNF therapy in accordance with current pediatric guidelines for the treatment of pediatric IBD 3. Active inflammation supported by CRP \> 5mg/L and /or FC \> 150 μg/g before the 1st IFX dose
Exclusion criteria
1. Consent withdrawal, 2. Stenosing or penetrating disease requiring surgery, abdominal abscess, symptomatic stricture, 3. Abdominal surgery within the previous 6 months, 4. Acute severe ulcerative colitis attack defined by a PUCAI score Ñ 65, 5. Infective contraindication to IFX treatment including positive tuberculin skin test or Quantiferon-TB test, recent opportunistic infection, infection with hepatitis B (HBV), C (HCV), human immunodeficiency virus (HIV), 6. Previous exposure to anti-TNF; 7. Exposure to concomitant prohibited medications including other biologics (including but not limited to ustekinumab, vedolizumab, abatacept, anakinra..), thalidomide, investigational drugs 8. Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of IFX discontinuation or need for treatment intensification due to non-response or LOR during the first year of treatment. | 54 weeks | Composite outcome. Treatment intensification is defined as adjunction of rescue therapies, including corticosteroids systemic or topical, azathioprine (AZA), methotrexate (MTX), 5-aminosalicylate (5-ASA) systemic or topical, or rescue IFX escalation or surgery; treatment response is defined as a decrease in Pediatric Crohn's Disease Activity Index (PCDAI) by 12.5 point or in Pediatric Ulcerative Colitis Activity Index (PUCAI) by 10 points with decrease in C reactive protein (CRP) by 50% after induction, evaluated between 12-14 weeks; loss of response (LOR) is defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5mg/dl and/or fecal calprotectin (FC) \>250 microg/g in a patient who previously responded to induction treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of subtherapeutic IFX concentrations | 54 weeks | Subtherapeutic IFX concentration is defined as IFX concentration at trough \< 5 microg/ml (or \<10 microg/ml in perianal CD) during maintenance treatment. |
| Cumulative probability of Loss of Response | 54 weeks | Time to Loss of Response (LOR), with LOR defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5 mg/dl and/or FC \>250 microg/g in a patient who previously responded to induction treatment. |
| Frequency of Anti-Infliximab Antibodies | 54 weeks | Evaluation of Anti-Infliximab Antibodies |
| Frequency of infusion reactions | 54 weeks | Infusion reactions are defined as reactions that develop during the course of the infusion or within 1-2h of its completion. |
| Cumulative probability of IFX discontinuation | 54 weeks | Time to IFX discontinuation |
| Frequency of patients with treatment response at the end of induction between 12 and 14 weeks | Week 14 | Treatment response is defined as a decrease in PCDAI by 12.5 point or in PUCAI by 10 points with decrease in CRP by 50% compared to baseline |
| Frequency of patients with clinical remission at 14 weeks | Week 14 | Clinical remission is defined as PCDAI \<10 or PUCAI \<10 |
| Frequency of clinical and biochemical remission at week 14 | Week 14 | Clinical and Biochemical remission is defined as PCDAI \<10 or PUCAI \<10 with CRP \< 0.5 mg/dl and FC \< 250 microg/g |
| Frequency of endoscopic remission | 54 weeks | Endoscopic remission is defined in patients with Crohn's Disease as a Simple Endoscopic score for Crohn's Disease (SES-CD score) less than or equal to (\<=) 2 and in patients with Ulcerative Colitis as a Mayo sub-score \<= 1 |
Countries
Italy
Contacts
Primary ContactSara Lega, MD PhD
Backup ContactSara Lega
Outcome results
None listed